Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
Publication
, Journal Article
Moul, JW; Dawson, N
Published in: Cancer Invest
January 2012
The development of new therapies for castration-resistant prostate cancer (CRPC) has increasingly focused on improving patient quality of life, mainly because of limited survival gains and continuing high morbidity burden from disease progression or the adverse effects of treatments. However, there is no generally accepted quality of life instrument for use with this patient group. This paper objectively reviews the existing literature and assesses the impact of CRPC treatments on patients' quality of life. The review also provides a narrative description of the evolving role of quality of life measures in clinical trials, and critiques the most widely used instruments.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 2012
Volume
30
Issue
1
Start / End Page
1 / 12
Location
England
Related Subject Headings
- Taxoids
- Survival
- Surveys and Questionnaires
- Quality of Life
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- Estramustine
Citation
APA
Chicago
ICMJE
MLA
NLM
Moul, J. W., & Dawson, N. (2012). Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest, 30(1), 1–12. https://doi.org/10.3109/07357907.2011.629381
Moul, Judd W., and Nancy Dawson. “Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.” Cancer Invest 30, no. 1 (January 2012): 1–12. https://doi.org/10.3109/07357907.2011.629381.
Moul JW, Dawson N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest. 2012 Jan;30(1):1–12.
Moul, Judd W., and Nancy Dawson. “Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.” Cancer Invest, vol. 30, no. 1, Jan. 2012, pp. 1–12. Pubmed, doi:10.3109/07357907.2011.629381.
Moul JW, Dawson N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Invest. 2012 Jan;30(1):1–12.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
January 2012
Volume
30
Issue
1
Start / End Page
1 / 12
Location
England
Related Subject Headings
- Taxoids
- Survival
- Surveys and Questionnaires
- Quality of Life
- Prostatic Neoplasms
- Prostate-Specific Antigen
- Oncology & Carcinogenesis
- Male
- Humans
- Estramustine